These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 9918905)
1. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Invernizzi P; Setchell KD; Crosignani A; Battezzati PM; Larghi A; O'Connell NC; Podda M Hepatology; 1999 Feb; 29(2):320-7. PubMed ID: 9918905 [TBL] [Abstract][Full Text] [Related]
2. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Setchell KD; Rodrigues CM; Podda M; Crosignani A Gut; 1996 Mar; 38(3):439-46. PubMed ID: 8675100 [TBL] [Abstract][Full Text] [Related]
4. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Crosignani A; Podda M; Battezzati PM; Bertolini E; Zuin M; Watson D; Setchell KD Hepatology; 1991 Dec; 14(6):1000-7. PubMed ID: 1959845 [TBL] [Abstract][Full Text] [Related]
5. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Batta AK; Salen G; Mirchandani R; Tint GS; Shefer S; Batta M; Abroon J; O'Brien CB; Senior JR Am J Gastroenterol; 1993 May; 88(5):691-700. PubMed ID: 8480734 [TBL] [Abstract][Full Text] [Related]
7. Effect of tauroursodeoxycholic acid on biliary lipid composition. A dose-response study. Muraca M; Vilei MT; Cianci V; Liu XT; Garotta F Int J Clin Pharmacol Ther; 1995 Jul; 33(7):391-3. PubMed ID: 7582394 [TBL] [Abstract][Full Text] [Related]
8. Studies of serum and feces bile acids determination by gas chromatography-mass spectrometry. Tadano T; Kanoh M; Matsumoto M; Sakamoto K; Kamano T Rinsho Byori; 2006 Feb; 54(2):103-10. PubMed ID: 16548228 [TBL] [Abstract][Full Text] [Related]
9. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767 [TBL] [Abstract][Full Text] [Related]
10. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Crosignani A; Podda M; Bertolini E; Battezzati PM; Zuin M; Setchell KD Hepatology; 1991 Jun; 13(6):1076-83. PubMed ID: 2050325 [TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment. Setchell KD; Galzigna L; O'Connell N; Brunetti G; Tauschel HD Aliment Pharmacol Ther; 2005 Mar; 21(6):709-21. PubMed ID: 15771757 [TBL] [Abstract][Full Text] [Related]
12. Effect of ursodeoxycholate and its taurine conjugate on bile acid synthesis and cholesterol absorption. Hardison WG; Grundy SM Gastroenterology; 1984 Jul; 87(1):130-5. PubMed ID: 6724255 [TBL] [Abstract][Full Text] [Related]
13. [Conjugated bile acid profiles in serum, urine, and bile of patients with primary biliary cirrhosis under the ursodeoxycholic acid treatment]. Aoshima M; Nakamura K; Makino I Hokkaido Igaku Zasshi; 1995 Jan; 70(1):57-67. PubMed ID: 7744371 [TBL] [Abstract][Full Text] [Related]
14. The choleretic effects of N-acetylglucosaminides, major urinary metabolites of ursodeoxycholic acid, in bile fistula rats. Iwaki T; Hirabayashi N; Miyazawa N; Takeuchi Y; Ishizaki K; Sakakura H; Kasai H; Maeda M; Araki T Eur J Pharmacol; 1998 Dec; 363(1):41-8. PubMed ID: 9877080 [TBL] [Abstract][Full Text] [Related]
15. A new amino acid derivative of ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to selectively release UDCA in the colon. Asciutti S; Castellani D; Nardi E; Morelli O; Clementi M; Chistolini F; Gentili G; Setchell KD; O'Connell N; Pellicciari R; Clerici C Anticancer Res; 2009 Dec; 29(12):4971-9. PubMed ID: 20044604 [TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Krähenbühl S; Fischer S; Talos C; Reichen J Hepatology; 1994 Dec; 20(6):1595-601. PubMed ID: 7982660 [TBL] [Abstract][Full Text] [Related]
17. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Batta AK; Salen G; Holubec H; Brasitus TA; Alberts D; Earnest DL Cancer Res; 1998 Apr; 58(8):1684-7. PubMed ID: 9563483 [TBL] [Abstract][Full Text] [Related]
18. Effects of biliary bile acid composition on biliary cholesterol saturation in gallstone patients treated with chenodeoxycholic acid and/or ursodeoxycholic acid. Stiehl A; Raedsch R; Czygan P; Götz R; Männer C; Walker S; Kommerell B Gastroenterology; 1980 Dec; 79(6):1192-8. PubMed ID: 7439628 [TBL] [Abstract][Full Text] [Related]
19. Quantification of individual serum bile acids in patients with liver diseases using high-performance liquid chromatography. Okuda H; Obata H; Nakanishi T; Hisamitsu T; Matsubara K; Watanabe H Hepatogastroenterology; 1984 Aug; 31(4):168-71. PubMed ID: 6479837 [TBL] [Abstract][Full Text] [Related]
20. Comparative formation of lithocholic acid from chenodeoxycholic and ursodeoxycholic acids in the colon. Bazzoli F; Fromm H; Sarva RP; Sembrat RF; Ceryak S Gastroenterology; 1982 Oct; 83(4):753-60. PubMed ID: 7106506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]